Day, James W;
Fox, Thomas A;
Gupta, Rajeev;
Khwaja, Asim;
Wilson, Andrew J;
Kottaridis, Panagiotis D;
(2022)
Gilteritinib monotherapy as a transplant bridging option for high risk FLT3-mutated AML with t(6;9)(p23;q34.1);DEK-NUP214 in morphological but not cytogenetic or molecular remission following standard induction chemotherapy.
Leukemia Research Reports
, 17
, Article 100291. 10.1016/j.lrr.2022.100291.
Preview |
Text
Day_1-s2.0-S2213048922000036-main.pdf - Published Version Download (288kB) | Preview |
Abstract
We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an alternative consolidation treatment option rather than further intensive chemotherapy. Gilteritinib was able to achieve complete molecular and cytogenetic remission despite the additional cytogenetic abnormality. This case provides supporting evidence for the use of single agent gilteritinib in high-risk primary refractory FLT3-mutated AML with t(6;9) prior to transplantation.
Archive Staff Only
 |
View Item |
